Tango Therapeutics (NASDAQ:TNGX) is preparing to move further into late-stage development for its PRMT5 inhibitor vopimetostat, newly appointed CEO Malte Peters said during a Guggenheim fireside chat. Peters, who has served on Tango’s board since 2018, told attendees the company should not expect a “drastic strategic change” following his transition into the CEO role. Peters […]